ReNeuron Group (LSE:RENE) Total Equity : £2.42 Mil (As of Sep. 2023)

View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Total Equity?

ReNeuron Group's total equity for the quarter that ended in Sep. 2023 was £2.42 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

ReNeuron Group Total Equity Historical Data

The historical data trend for ReNeuron Group's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Total Equity Chart

ReNeuron Group Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Equity

Get a 7-Day Free Trial

23.24

13.22

18.91

9.89

5.06

ReNeuron Group Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Equity	Get a 7-Day Free Trial															14.15	9.89	7.08	5.06	2.42

ReNeuron Group Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ReNeuron Group's Total Equity for the fiscal year that ended in Mar. 2023 is calculated as

Total Equity	=	Total Assets(Q: Mar. 2023 )	-	Total Liabilities(Q: Mar. 2023 )
	=	9.645	-	4.588
	=	5.06

ReNeuron Group's Total Equity for the quarter that ended in Sep. 2023 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2023 )	-	Total Liabilities(Q: Sep. 2023 )
	=	6.423	-	4.002
	=	2.42

ReNeuron Group Total Equity Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (LSE:RENE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

RNUGF:USA RENE.GB:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.